{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:20:44Z","timestamp":1789701644902,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T00:00:00Z","timestamp":1306368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00280-011-1679-8","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T04:55:14Z","timestamp":1306299314000},"page":"107-113","source":"Crossref","is-referenced-by-count":44,"title":["Hematologic adverse events associated with temozolomide"],"prefix":"10.1007","volume":"69","author":[{"given":"J. Lee","family":"Villano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Letarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janny M.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Abdur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,26]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1215\/15228517-2008-120","volume":"11","author":"TS Armstrong","year":"2009","unstructured":"Armstrong TS, Cao Y, Scheurer ME, Vera-Bolanos E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 11:825\u2013832","journal-title":"Neuro Oncol"},{"key":"1679_CR2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/11319000-000000000-00000","volume":"33","author":"S Bailey","year":"2010","unstructured":"Bailey S, Singh A, Azadian R, Huber P, Blum M (2010) Prospective data mining of six products in the US FDA adverse event reporting system: disposition of events identified and impact on product safety profiles. Drug Saf 33:139\u2013146","journal-title":"Drug Saf"},{"key":"1679_CR3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/cncr.21808","volume":"106","author":"SM Belknap","year":"2006","unstructured":"Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051\u20132057","journal-title":"Cancer"},{"key":"1679_CR4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.dnarep.2007.02.008","volume":"6","author":"M Briegert","year":"2007","unstructured":"Briegert M, Enk AH, Kaina B (2007) Change in expression of MGMT during maturation of human monocytes into dendritic cells. DNA Repair (Amst) 6:1255\u20131263","journal-title":"DNA Repair (Amst)"},{"key":"1679_CR5","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"1679_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-008-9764-5","volume":"93","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC, Raizer J (2009) Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol 93:229\u2013232","journal-title":"J Neurooncol"},{"key":"1679_CR7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00277-005-1093-6","volume":"84","author":"S Vita De","year":"2005","unstructured":"De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A, Leone G, Sica S (2005) Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 84:760\u2013762","journal-title":"Ann Hematol"},{"key":"1679_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.blre.2007.11.003","volume":"22","author":"I Dokal","year":"2008","unstructured":"Dokal I, Vulliamy T (2008) Inherited aplastic anaemias\/bone marrow failure syndromes. Blood Rev 22:141\u2013153","journal-title":"Blood Rev"},{"key":"1679_CR9","doi-asserted-by":"crossref","unstructured":"Doyle TJ, Mikkelsen T, Croteau D, Ali H, Anderson J, Beasse R, Rogers L, Rosenblum M, Ryu S (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a phase II trial. J Clin Oncol 23: (abstract # 1546)","DOI":"10.1200\/jco.2005.23.16_suppl.1546"},{"key":"1679_CR10","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.dnarep.2004.05.004","volume":"3","author":"F Drablos","year":"2004","unstructured":"Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, Pena-Diaz J, Otterlei M, Slupphaug G, Krokan HE (2004) Alkylation damage in DNA and RNA\u2013repair mechanisms and medical significance. DNA Repair (Amst) 3:1389\u20131407","journal-title":"DNA Repair (Amst)"},{"key":"1679_CR11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bcp.2007.09.022","volume":"75","author":"Q Fang","year":"2008","unstructured":"Fang Q, Loktionova NA, Moschel RC, Javanmard S, Pauly GT, Pegg AE (2008) Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase. Biochem Pharmacol 75:618\u2013626","journal-title":"Biochem Pharmacol"},{"key":"1679_CR12","first-page":"7","volume":"1","author":"F DA","year":"2007","unstructured":"DA F (2007) Temozolomide (marketed as Temodar): aplastic anemia. Drug Saf Newsl 1:7","journal-title":"Drug Saf Newsl"},{"key":"1679_CR13","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2005-09-3649","volume":"107","author":"H Geiger","year":"2006","unstructured":"Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD (2006) Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 107:3010\u20133011","journal-title":"Blood"},{"key":"1679_CR14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/SMJ.0b013e3181b1d2fa","volume":"102","author":"BJ George","year":"2009","unstructured":"George BJ, Eichinger JB, Richard TJ (2009) A rare case of aplastic anemia caused by temozolomide. South Med J 102:974\u2013976","journal-title":"South Med J"},{"key":"1679_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1215\/15228517-2006-024","volume":"9","author":"DE Gerber","year":"2007","unstructured":"Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47\u201352","journal-title":"Neuro Oncol"},{"key":"1679_CR16","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood.V88.5.1649.1649","volume":"88","author":"SL Gerson","year":"1996","unstructured":"Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C (1996) Human CD34\u00a0+\u00a0hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 88:1649\u20131655","journal-title":"Blood"},{"key":"1679_CR17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/mutage\/14.3.339","volume":"14","author":"BJ Glassner","year":"1999","unstructured":"Glassner BJ, Weeda G, Allan JM, Broekhof JL, Carls NH, Donker I, Engelward BP, Hampson RJ, Hersmus R, Hickman MJ, Roth RB, Warren HB, Wu MM, Hoeijmakers JH, Samson LD (1999) DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis 14:339\u2013347","journal-title":"Mutagenesis"},{"key":"1679_CR18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/carcin\/bgl218","volume":"28","author":"RJ Hansen","year":"2007","unstructured":"Hansen RJ, Nagasubramanian R, Delaney SM, Samson LD, Dolan ME (2007) Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28:1111\u20131116","journal-title":"Carcinogenesis"},{"key":"1679_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cncr.23988","volume":"115","author":"N Hijiya","year":"2009","unstructured":"Hijiya N, Ness KK, Ribeiro RC, Hudson MM (2009) Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 115:23\u201335","journal-title":"Cancer"},{"key":"1679_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-007-9398-z","volume":"85","author":"R Jalali","year":"2007","unstructured":"Jalali R, Singh P, Menon H, Gujral S (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 85:105\u2013107","journal-title":"J Neurooncol"},{"key":"1679_CR21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biochi.2003.10.007","volume":"85","author":"P Karran","year":"2003","unstructured":"Karran P, Offman J, Bignami M (2003) Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 85:1149\u20131160","journal-title":"Biochimie"},{"key":"1679_CR22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ (2007) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 31:599\u2013604","journal-title":"Leuk Res"},{"key":"1679_CR23","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-08-0320","volume":"68","author":"MD Milsom","year":"2008","unstructured":"Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA (2008) Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res 68:6171\u20136180","journal-title":"Cancer Res"},{"key":"1679_CR24","first-page":"396","volume":"10","author":"B Morris","year":"2008","unstructured":"Morris B, Reiss U, Kasow K, Broniscer A (2008) Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM). Neuro-Oncol 10:396 (abstract CR2)","journal-title":"Neuro-Oncol"},{"key":"1679_CR25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11060-008-9754-7","volume":"92","author":"M Nagane","year":"2009","unstructured":"Nagane M, Nozue K, Shimizu S, Waha A, Miyazaki H, Kurita H, Homori M, Fujioka Y, Shiokawa Y (2009) Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma\u2013analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 92:227\u2013232","journal-title":"J Neurooncol"},{"key":"1679_CR26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1215\/15228517-2006-003","volume":"8","author":"V Noronha","year":"2006","unstructured":"Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW (2006) Treatment-related myelodysplasia\/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 8:280\u2013283","journal-title":"Neuro Oncol"},{"key":"1679_CR27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","volume":"22","author":"J Pedersen-Bjergaard","year":"2008","unstructured":"Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH (2008) Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22:240\u2013248","journal-title":"Leukemia"},{"key":"1679_CR28","doi-asserted-by":"crossref","unstructured":"Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP, Middleton MR (2009) Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res. doi: 10.1097\/CMR.0b013e32832ccd58","DOI":"10.1097\/CMR.0b013e32832ccd58"},{"key":"1679_CR29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2007.06613.x","volume":"137","author":"C Seedhouse","year":"2007","unstructured":"Seedhouse C, Russell N (2007) Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol 137:513\u2013529","journal-title":"Br J Haematol"},{"key":"1679_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-007-9403-6","volume":"85","author":"N Singhal","year":"2007","unstructured":"Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 85:229\u2013230","journal-title":"J Neurooncol"},{"key":"1679_CR31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"1679_CR32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-004-2028-0","volume":"71","author":"YW Su","year":"2005","unstructured":"Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 71:315\u2013318","journal-title":"J Neurooncol"},{"key":"1679_CR33","first-page":"630","volume":"11","author":"R Thind","year":"2009","unstructured":"Thind R, Torcuator RG, Doyle TJ, Andersen J, Loutfi R, Haythem A, Remer S, Schultz L, Mikkelsen T (2009) The role of demographic and genetic factors in temozolomide-related severe myelotoxicity. Neuro Oncol 11:630","journal-title":"Neuro Oncol"},{"key":"1679_CR34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(06)70696-9","volume":"7","author":"JL Villano","year":"2006","unstructured":"Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436\u2013438","journal-title":"Lancet Oncol"},{"key":"1679_CR35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-009-1050-5","volume":"64","author":"JL Villano","year":"2009","unstructured":"Villano JL, Seery TE, Bressler LR (2009) Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64:647\u2013655","journal-title":"Cancer Chemother Pharmacol"},{"key":"1679_CR36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/jmg.2007.053850","volume":"45","author":"LJ Worrillow","year":"2008","unstructured":"Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM (2008) Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 45:142\u2013146","journal-title":"J Med Genet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1679-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1679-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T14:31:43Z","timestamp":1592577103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,26]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1679-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,26]]}}}